Thomas H Callisen graduated with a PhD in biophysics in 1994 from DTU, Technical University of Denmark. From 1994 until 1998 he was Postdoc and Assistant Professor in US and DK. In 1998, Thomas was employed by Novo Nordisk as principal scientist, and later as senior manager at Novozymes. In 2020, Thomas started as CEO at Sense Unlimited. Thomas has been driving biophysical and nano-science discoveries with applications within biotech, food, material and healthcare. His collaborations across academia and business collaborations have lead to co-authorship of 14 patents and 42 science publications.